Видео ютуба по тегу Bcma X Cd3

Linvoseltamab (LYNOZYFIC ) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
Linvoseltamab (LYNOZYFIC ) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
Teclistamab (TECVAYLI) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
Teclistamab (TECVAYLI) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma
Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma
Phase I study of teclistamab, a humanized BCMA x CD3 bispecific antibody, in relapsed/refractory MM
Phase I study of teclistamab, a humanized BCMA x CD3 bispecific antibody, in relapsed/refractory MM
Teclistamab: BCMA x CD3 bispecific antibody in RRMM
Teclistamab: BCMA x CD3 bispecific antibody in RRMM
180 Updated Phase 1 Results of Teclistamab, a BCMA x CD3 Bispecific Antibody
180 Updated Phase 1 Results of Teclistamab, a BCMA x CD3 Bispecific Antibody
Elranatamab (ELREXFIO) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
Elranatamab (ELREXFIO) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
Alnuctamab, a BCMA x CD3 T-Cell Engager, in Pts with Relapsed/Refractory Multiple Myeloma
Alnuctamab, a BCMA x CD3 T-Cell Engager, in Pts with Relapsed/Refractory Multiple Myeloma
First-in-Human Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Pts w/RRMM
First-in-Human Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Pts w/RRMM
ASH23: Abbv-383 BCMA x CD3 Bispecific Antibody for Relapsed/Refractory Myeloma | Ravi Vij, MD, MBA
ASH23: Abbv-383 BCMA x CD3 Bispecific Antibody for Relapsed/Refractory Myeloma | Ravi Vij, MD, MBA
Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R/R myeloma
Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R/R myeloma
REGN5459, a BCMA×CD3 bispecific antibody, in R/R multiple myeloma
REGN5459, a BCMA×CD3 bispecific antibody, in R/R multiple myeloma
Bispecific BCMA-CD3 antibody teclistamab is efficacious and tolerable in R/R MM
Bispecific BCMA-CD3 antibody teclistamab is efficacious and tolerable in R/R MM
Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results
Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results
Phase I trial of a BCMA-CD3 bispecific antibody in R/R myeloma
Phase I trial of a BCMA-CD3 bispecific antibody in R/R myeloma
SC vs. IV administration of a BCMA-CD3 bispecific antibody for R/R myeloma
SC vs. IV administration of a BCMA-CD3 bispecific antibody for R/R myeloma
Updated data: Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody
Updated data: Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody
Updated phase 1 results of teclistamab, a BCMA × CD3 bispecific antibody, in RRMM
Updated phase 1 results of teclistamab, a BCMA × CD3 bispecific antibody, in RRMM
Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMM
Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMM
Exciting results for BCMA/CD3 bispecific elranatamab (PF-3135) in R/R MM
Exciting results for BCMA/CD3 bispecific elranatamab (PF-3135) in R/R MM